Thrombocytopenia and Platelet Transfusions in Patients with Cancer

  • Jason Valent
  • Charles A. Schiffer
Part of the Cancer Treatment and Research book series (CTAR, volume 157)


Platelet transfusions are a critical component of the supportive care for patients receiving intensive therapy for hematologic malignancies. The platelet count “triggering” prophylactic transfusion has decreased over the years, and studies comparing a prophylactic versus a therapeutic transfusion approach are in progress. The evidence supporting the need for platelet transfusions prior to different invasive procedures is reviewed. Lastly, studies evaluating the use of thrombopoietic stimulating agents to reduce hemorrhage and decrease the need for platelet transfusions are discussed. To date, there is no evidence that this approach is of clinical utility.


Thrombocytopenia Platelet Transfusions Cancer 


  1. 1.
    Hersh EM, Bodey GP, Nies BA, et al. Causes of death in acute leukemia. JAMA. 1965;193:105–9.PubMedGoogle Scholar
  2. 2.
    Han T, Stutzman L, Cohen E, et al. Effect of platelet transfusion on hemorrhage in patients with acute leukemia. Cancer. 1966;19:1937–42.CrossRefPubMedGoogle Scholar
  3. 3.
    Sullivan MT, Wallace EL. Blood collection and transfusion in the United States in 1999. Transfusion. 2005;45:141–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1519–38.PubMedGoogle Scholar
  5. 5.
    British Committee for Standards in Haematology, Blood Transfusion Task Force (Chairman P. Kelsey). Guidelines for the use of platelet transfusions. Br J Haematol. 2003;122:10–23.Google Scholar
  6. 6.
    Slichter SJ. Evidenced-based platelet transfusion guidelines. Hematology. 2007;2007:172–8.CrossRefGoogle Scholar
  7. 7.
    Gaydos LA, Freireich EJ, Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med. 1962;266:905–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Higby DJ, Cohen E, Holland JF, et al. The prophylactic treatment of thrombocytopenic leukemic patients with platelets: a double blind study. Transfusion. 1974;14:440–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Roy AJ, Jaffe N, Djerassi I. Prophylactic platelet transfusions in children with acute leukemia: a dose response study. Transfusion. 1973;13(5):283–90.CrossRefPubMedGoogle Scholar
  10. 10.
    Murphy S, Litwin S, Herring LM, et al. Indications for platelet transfusion in children with acute leukemia. Am J Hematol. 1982;12:347–56.CrossRefPubMedGoogle Scholar
  11. 11.
    Gmür J, Burger J, Schanz U, et al. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. Lancet. 1991;338:1223–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Heckman KD, Weiner GJ, Davis CS, et al. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/μL versus 20,000/μL. J Clin Oncol. 1997;15(3):1143–9.PubMedGoogle Scholar
  13. 13.
    Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. N Engl J Med. 1997;337:1870–5.CrossRefPubMedGoogle Scholar
  14. 14.
    Wandt H, Frank M, Ehninger G, et al. Safety and cost effectiveness of a 10 × 109/L trigger for prophylactic platelet transfusions compared with the traditional 20 × 109/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood. 1998;91:3601–6.PubMedGoogle Scholar
  15. 15.
    Friedmann AM, Sengul H, Lehmann H, et al. Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients? A re-evaluation of prophylactic platelet transfusions. Transfus Med Rev. 2002;16:34–45.CrossRefPubMedGoogle Scholar
  16. 16.
    Rudmann SV. Textbook of blood banking and transfusion medicine,  Chapter 14. Philadelphia, PA: W.B. Saunders an Co; 2005. p. 380.Google Scholar
  17. 17.
    Folman CC, de Jong SM, de Haas M, et al. Analysis of the kinetics of TPO uptake during platelet transfusion. Transfusion. 2001;41:517–21.CrossRefPubMedGoogle Scholar
  18. 18.
    Slichter S, Kaufman R, Assmann S, et al. Effects of prophylactic platelet dose on transfusion outcomes (PLADO trial). Blood (ASH Annual Meeting Abstracts). 2008;112. Abstract 285.Google Scholar
  19. 19.
    Heddle N, Cook R, Tinmouth A, et al. A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood (ASH Annual Meeting Abstracts). 2009;113:1564–73.CrossRefPubMedGoogle Scholar
  20. 20.
    Wandt H, Schaefer-Eckart K, Frank M, et al. A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 2006;37:387–92.CrossRefPubMedGoogle Scholar
  21. 21.
    Wandt H, Wendelin K, Schaefer-Eckart K, et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts). 2008;112. Abstract 286.Google Scholar
  22. 22.
    Blajchman M, Slichter S, Heddle N, et al. New strategies for the optimal use of platelet transfusions. Am Soc of Hematol Educ Program. 2008;198–204.Google Scholar
  23. 23.
    Edelson RN, Chernik NL, Posner JB. Spinal subdural hematomas complicating lumbar puncture. Arch Neurol. 1974;31:134–7.PubMedGoogle Scholar
  24. 24.
    Breuer AC, Tyler R, Marzewski DJ, et al. Radicular vessels are the most probable source of needle induced blood in lumbar puncture. Cancer. 1982;49:2168–72.CrossRefPubMedGoogle Scholar
  25. 25.
    Howard SC, Gajjar A, Ribeiro RC, et al. Safety of lumbar puncture for children with acute lymphoblastic leukemia and thrombocytopenia. JAMA. 2000;284(17):2222–4.CrossRefPubMedGoogle Scholar
  26. 26.
    Bishop JF, Schiffer CA, Aisner J, et al. Surgery in acute leukemia: a review of 167 operations in thrombocytopenic patients. Am J Hematol. 1987;26:147–55.CrossRefPubMedGoogle Scholar
  27. 27.
    National Institutes of Health Consensus Conference. Platelet transfusion therapy. Transfus Med Rev. 1987;1:195–200.Google Scholar
  28. 28.
    Norfolk DR, Ancliffe PJ, Contreras M, et al. Consensus conference on platelet transfusion. Royal College of Physicians of Edinburgh, 27–28 November 1997. Br J Haematol. 1998;101:609–17.CrossRefPubMedGoogle Scholar
  29. 29.
    McVay PA, Toy PT. Lack of increased bleeding after liver biopsy in patients with mild hemostatic abnormalities. Am J Clin Pathol. 1990;94:747–53.PubMedGoogle Scholar
  30. 30.
    Williford SK, Salisbury PL III, Peacock JE Jr, et al. The safety of dental extractions in patients with hematologic malignancies. J Clin Oncol. 1989;7:798–802.PubMedGoogle Scholar
  31. 31.
    Overholser CD, Peterson DE, Bergman SA, et al. Dental extractions in patients with acute nonlymphocytic leukemia. J Oral Maxillofac Surg. 1982;40:296–8.CrossRefPubMedGoogle Scholar
  32. 32.
    Doerfler ME, Kaufman B, Goldenberg AS. Central venous catheter placement in patients with disorders of hemostasis. Chest. 1996;110:185–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Stellato TA, Gauderer MW, Lazarus HM, et al. Percutaneous isoelastic catheter insertion in patients with thrombocytopenia. Cancer. 1985;56:2691–3.CrossRefPubMedGoogle Scholar
  34. 34.
    Chu DZJ, Shivshanker K, Stroehlein JR, et al. Thrombocytopenia and gastrointestinal hemorrhage in the cancer patient: prevalence of unmasked lesions. Gastrointest Endosc. 1983;29:269–72.CrossRefPubMedGoogle Scholar
  35. 35.
    Weiss SM, Hert RC, Gianola FJ, et al. Complications of fiberoptic bronchoscopy in thrombocytopenic patients. Chest. 1993;104:1025–8.CrossRefPubMedGoogle Scholar
  36. 36.
    Papin TA, Lynch JP III, Weg JG. Transbronchial biopsy in the thrombocytopenic patient. Chest. 1985;88:549–52.CrossRefPubMedGoogle Scholar
  37. 37.
    Wallace MJ, Narvios A, Lichtiger B, et al. Transjugular liver biopsy in patients with hematologic malignancy and severe thrombocytopenia. J Vasc Interv Radiol. 2003;14(3):323–7.PubMedGoogle Scholar
  38. 38.
    Kluge S, Meyer A, Kühnelt P, et al. Percutaneous tracheostomy is safe in patients with severe thrombocytopenia. Chest. 2004;126(2):547–51.CrossRefPubMedGoogle Scholar
  39. 39.
    O’Connell BA, Lee EJ, Schiffer CA. The value of 10-minute post transfusion platelet counts. Transfusion. 1988;26:66–7.CrossRefGoogle Scholar
  40. 40.
    Basser RL, Rasko JEJ, Clarke K, et al. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood. 1997;89:3118–28.PubMedGoogle Scholar
  41. 41.
    Vadhan-Raj S, Patel S, Bueso-Ramos C, et al. Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia. J Clin Oncol. 2003;21:3158–67.CrossRefPubMedGoogle Scholar
  42. 42.
    Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med. 2000;132:364–8.PubMedGoogle Scholar
  43. 43.
    Fanucchi M, Glaspy J, Crawford J, et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med. 1997;336:404–9.CrossRefPubMedGoogle Scholar
  44. 44.
    Schuster MW, Beveridge R, Frei-Lahr D, et al. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation. Exp Hematol. 2002;30:1044–50.CrossRefPubMedGoogle Scholar
  45. 45.
    Archimbaud E, Ottmann OG, Liu-Yan JA, et al. A randomized, double-blind, placebo controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood. 1999;94:3694–701.PubMedGoogle Scholar
  46. 46.
    Schiffer CA, Miller K, Larson RA, et al. A doubleblind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood. 2000;95:2530–5.PubMedGoogle Scholar
  47. 47.
    Stone RM, Larson RA, Miller K, et al. A randomized, placebo-controlled, double-blind trial of a loading dose of pegylated recombinant human megakaryocytic growth and development factor (MGDF) as an adjunct to chemotherapy for acute myeloid leukemia (AML). ASCO. 2000;19:14.Google Scholar
  48. 48.
    Kaushansky K. Thrombopoietin: the primary regulator of platelet production. Blood. 1995;86:419–31.PubMedGoogle Scholar
  49. 49.
    Emmons RVB, Reid DM, Cohen RL, et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood. 1996;87:4068–71.PubMedGoogle Scholar
  50. 50.
    Komatsu N, Okamoto T, Yoshida T, et al. Pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) increased platelet counts (plt) in patients with aplastic anemia (AA) and myelodysplastic syndrome (MDS) [abstract]. Blood. 2000;96:296a.Google Scholar
  51. 51.
    Kuter D, Goodnough L, Romo J, et al. Thrombopoietin therapy increases platelet yields in healthy platelet donors. Blood. 2001;98:1339–45.CrossRefPubMedGoogle Scholar
  52. 52.
    Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001;98:3241–8.CrossRefPubMedGoogle Scholar
  53. 53.
    Vadhan-Raj S, Murray LJ, Bueso-Ramos C, et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med. 1997;126:673–81.PubMedGoogle Scholar
  54. 54.
    Tepler I, Elias L, Smith J II, et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood. 1996;87:3607–14.PubMedGoogle Scholar
  55. 55.
    Vredenburgh J, Hussein A, Fisher D, et al. A randomized trial of recombinant human interleukin-11 following autologous bone marrow transplantation with peripheral blood progenitor cell support in patients with breast cancer. Biol Blood Marrow Transplant. 1998;4:134–41.PubMedGoogle Scholar
  56. 56.
    Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis stimulating protein, for chronic ITP. N Engl J Med. 2006;355:1672–81.CrossRefPubMedGoogle Scholar
  57. 57.
    Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357:2237–47.CrossRefPubMedGoogle Scholar
  58. 58.
    Kantarjian H, Giles F, Greenberg P, et al. Effect of romiplostim in patients with low or intermediate risk myelodysplastic syndrome receiving azacytidine. Blood (ASH Annual Meeting Abstracts). 2008;112. Abstract 224.Google Scholar
  59. 59.
    Sekeres M, Kantarjian H, Fenaux P, et al. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with myelodysplastic syndrome. J Clin Oncol (ASCO Annual Meeting Proceedings) 2009;27:(15S). (May 20 Supplement). Abstract 7009.Google Scholar
  60. 60.
    The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med. 1997;337:1861–9.Google Scholar
  61. 61.
    Dutcher J, Schiffer CA, Aisner J, Wiernik PH. Alloimmunization following platelet transfusion: the absence of a dose response relationship. Blood. 1980;57:395–8.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Division of Hematology/OncologyKarmanos Cancer Institute, Wayne State UniversityDetroitUSA
  2. 2.Division of Hematology/OncologyKarmanos Cancer Institute, Wayne State University School of MedicineDetroitUSA

Personalised recommendations